In findings that have particular relevance in the COVID-19 pandemic, WA researchers have shown that ACE inhibitors and angiotensin receptor blockers (ARB) reduce the risk of pneumonia and influenza in people with type 2 diabetes. Use of ACE inhibitors or ARB was associated with a one third lower risk of hospitalisation for lower respiratory tract ...
Type 2 diabetes
Pneumonia protection may be another reason for people with T2D to take ACEi/ARB
By Michael Woodhead
23 Jul 2020